Craft

Biogen

Stock Price

$183.5

2024-10-29

Market Capitalization

$26.7 B

2024-10-29

Revenue

$9.9 B

FY, 2025

Biogen Summary

Company Summary

Overview
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. It offers medicines and therapies in the areas of lupus, multiple sclerosis, postpartum depression, spinal muscular atrophy, etc.
Type
Public
Status
Active
Founded
1978
HQ
Cambridge, MA, US | view all locations
Website
https://www.biogen.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Ginger Gregory

    Ginger Gregory, Chief Human Resources Officer

  • Fraser Hall

    Fraser Hall, President, Head of Intercontinental Region

  • Alisha Alaimo

    Alisha Alaimo, President, Head of North America

  • Wolfram Schmidt

    Wolfram Schmidt, President, Head of Europe

Operating MetricsView all

Products (Neuromuscular Diseases)

1

FY, 2022

Products (Alzheimer's Disease)

1
50.0%

FY, 2024

Products (Biosimilars)

5
25.0%

FY, 2024

LocationsView all

46 locations detected

  • Cambridge, MA HQ

    United States

    225 Binney St

  • Morrisville, NC

    United States

    5000 Davis Dr

  • South San Francisco, CA

    United States

    6000 Shoreline Ct #304

  • Vicente López, Buenos Aires

    Argentina

    7th Floor, Av. del Libertador 350

  • Macquarie Park, NSW

    Australia

    2 Banfield Rd

  • Wien, Wien

    Austria

    Rund Vier B, Stella-Klein-Löw-Weg 15

and 40 others

Biogen Financials

Summary Financials

Revenue (Q1, 2026)
$2.5B
Gross profit (Q1, 2026)
$1.8B
Net income (Q1, 2026)
$319.5M
Cash (Q1, 2026)
$2.5B
Enterprise value
$30.8B

Footer menu